WO2017208129A1 - Pharmaceutical composition and method for reducing intraocular pressure - Google Patents
Pharmaceutical composition and method for reducing intraocular pressure Download PDFInfo
- Publication number
- WO2017208129A1 WO2017208129A1 PCT/IB2017/053143 IB2017053143W WO2017208129A1 WO 2017208129 A1 WO2017208129 A1 WO 2017208129A1 IB 2017053143 W IB2017053143 W IB 2017053143W WO 2017208129 A1 WO2017208129 A1 WO 2017208129A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glaucoma
- pharmaceutically acceptable
- pharmaceutical composition
- racemate
- enantiomer
- Prior art date
Links
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 20
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 229940002612 prodrug Drugs 0.000 claims abstract description 21
- 239000000651 prodrug Substances 0.000 claims abstract description 21
- 239000012453 solvate Substances 0.000 claims abstract description 17
- NJRZGXLLFIJSBG-UHFFFAOYSA-N 1-cyano-2-(1-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-pyridin-3-ylguanidine Chemical compound CC1(C)N(O)C(C)(C)CC1NC(=NC#N)NC1=CC=CN=C1 NJRZGXLLFIJSBG-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 18
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 14
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims description 8
- 206010012565 Developmental glaucoma Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- 201000006366 primary open angle glaucoma Diseases 0.000 claims description 6
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 206010018325 Congenital glaucomas Diseases 0.000 claims description 4
- 206010074026 Exfoliation glaucoma Diseases 0.000 claims description 4
- 201000006336 Juvenile glaucoma Diseases 0.000 claims description 4
- 206010034798 Phacolytic glaucoma Diseases 0.000 claims description 4
- 206010035015 Pigmentary glaucoma Diseases 0.000 claims description 4
- 206010072686 Uveitic glaucoma Diseases 0.000 claims description 4
- 208000013001 absolute glaucoma Diseases 0.000 claims description 4
- 201000001326 acute closed-angle glaucoma Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 201000004949 exfoliation syndrome Diseases 0.000 claims description 4
- 229940012356 eye drops Drugs 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 208000028507 juvenile open angle glaucoma Diseases 0.000 claims description 4
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 4
- 201000005428 steroid-induced glaucoma Diseases 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 201000006397 traumatic glaucoma Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010030043 Ocular hypertension Diseases 0.000 abstract description 9
- -1 nitroxide free radical Chemical class 0.000 description 28
- 239000000203 mixture Substances 0.000 description 22
- 239000013543 active substance Substances 0.000 description 16
- 229910002092 carbon dioxide Inorganic materials 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 9
- 102000003846 Carbonic anhydrases Human genes 0.000 description 7
- 108090000209 Carbonic anhydrases Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000002159 anterior chamber Anatomy 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003733 optic disk Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001585 trabecular meshwork Anatomy 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010067013 Normal tension glaucoma Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940084896 gentak Drugs 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 201000002978 low tension glaucoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- 108700012439 CA9 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- the present invention relates to pharmaceutical composition and method for reducing intraocular pressure and thereby treating ocular hypertension and/or glaucoma.
- POAG Primary open angle glaucoma
- IOP intraocular pressure
- WO 2012/077108 discloses compounds composed of a potassium channel opener, e.g., a pyridinocyanoguanidine moiety or a derivative thereof, linked to a reactive oxygen species degradation catalyst comprising a nitroxide free radical (NO ' ) group, such as 3-amino-2,2,5,5-tetramethylpyrrolidinyloxy (3-amino- PROXYL), 4-amino-2,2,6,6-tetramethylpipperidinyloxy (4-amino-TEMPO), or a derivative thereof, and pharmaceutical compositions thereof.
- a potassium channel opener e.g., a pyridinocyanoguanidine moiety or a derivative thereof
- a reactive oxygen species degradation catalyst comprising a nitroxide free radical (NO ' ) group, such as 3-amino-2,2,5,5-tetramethylpyrrolidinyloxy (3-amino- PROXYL), 4-amino-2,2,6,6-tetra
- Such compounds are useful in treatment, prevention and/or managing of diseases, disorders and conditions associated with oxidative stress or endothelial dysfunction.
- One of the compounds exemplified in said publication is the oxy radical of 2-cyano-l-(l-hydroxy- 2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl) guanidine, herein identified R-801.
- R-801 is a highly potent inhibitor of human type 2 carbonic anhydrase (hCA), an enzyme controlling 95% of inflow into the anterior chamber, and thus highly beneficial, upon administration to the eye, in reducing IOP.
- hCA human type 2 carbonic anhydrase
- This compound can therefore be used for treatment of, e.g., ocular hypertension and/or glaucoma.
- the present invention thus provides a pharmaceutical composition
- a pharmaceutical composition comprising the oxy radical of 2-cyano-l-(l-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3- (pyridin-3-yl)guanidine (R-801), or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier or diluent, for reducing, i.e., lowering, IOP, more particularly for prevention or treatment of intraocular h ertension and/or glaucoma.
- the present invention relates to R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in reducing IOP.
- the present invention relates to use of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for reducing IOP.
- the present invention relates to a method for reducing, i.e., lowering, IOP in a subject in need thereof comprising administering to the eye of said subject a therapeutically effective amount of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- the subject treated by the method of the invention may be any mammal such as a human, non-human primate, horse, ferret dog, cat, cow, and goat; but it is preferably a human, i.e., an individual.
- Fig. 1 shows that after baseline stabilization of pressure, in anterior segments, the pressure dropped from 16 mmHg to 11 mmHg after R-801 (20 ⁇ ) was added to a human cadaver eye ( ⁇ ) while the fellow eye ( ⁇ ) received vehicle (DMSO). After 72 hours of treatment, drug and vehicle were removed from the eyes and perfused with DMEM. Following perfusion, the pressure in the eye that received R-801 returned to near baseline levels (actually a little higher), and relatively no change in pressure was observed in the eye treated with vehicle.
- Fig. 2 shows the effects of R-801-induced pressure reduction, in anterior segments, when the baseline pressure in a human cadaver eye ( ⁇ ) was 28 mmHg. This initial pressure was higher than normal, but it had a stable baseline. The pressure dropped from 28 mmHg to 16 mmHg following R-801 treatment. Relatively no change was observed in the vehicle-treated control eye ( ⁇ ). Perfusion was stopped after 18 hours.
- Fig. 3 shows the effects of R-801-induced pressure reduction, in the eye of a monkey that underwent laser treatment to induce ocular hypertension (OHT).
- IOP was measured with a calibrated pneumatonometer.
- R-801 treatment by intracameral injection reduced the IOP from 26 mmHg to 12 mmHg during the 30 hour period after treatment and returned to pretreatment levels after 96 hours.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, herein generally referred to as "the active/therapeutic agent", and a pharmaceutically acceptable carrier or diluent, for reducing IOP.
- intraocular hypertension refers to an intraocular pressure in an eye of a subject (e.g., a patient) that is above a normal level and is correlated as a risk factor for the development of visual field loss and glaucoma.
- Glaucoma is a heterogeneous group of optic neuropathies that share certain clinical features, wherein the loss of vision is due to the selective death of retinal ganglion cells in the neural retina that is clinically diagnosed by characteristic changes in the visual field, nerve fiber layer defects, and a progressive cupping of the optic nerve head.
- One of the main risk factors for the development of glaucoma is the presence of intraocular hypertension (elevated IOP). IOP also appears to be involved in the pathogenesis of normal tension glaucoma where patients have what is often considered to be normal IOP.
- the elevated IOP associated with glaucoma is due to elevated aqueous humor outflow resistance in the trabecular meshwork, a small- specialized tissue located in the iris-corneal angle of the ocular anterior chamber.
- Glaucomatous changes to the trabecular meshwork include a loss in trabecular meshwork cells and the deposition and accumulation of extracellular debris including proteinaceous plaque-like material.
- optic nerve head glial cells In glaucomatous eyes, there are morphological and mobility changes in optic nerve head glial cells.
- IOP and/or transient ischemic insults there is a change in the composition of the optic nerve head extracellular matrix and alterations in the glial cell and retinal ganglion cell axon morphologies.
- glaucoma refers to a disease of the eye characterized by increased pressure inside the eye with resultant optic nerve damage, and includes, without limiting, primary glaucoma, secondary glaucoma, juvenile glaucoma, congenital glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, phacolytic glaucoma, steroid-induced glaucoma, uveitic glaucoma, neovascular glaucoma, toxic glaucoma, traumatic glaucoma, acute angle closure glaucoma, absolute glaucoma, chronic glaucoma, narrow angle glaucoma, chronic open angle glaucoma, combined-mechanism glaucoma, simplex glaucoma and familial glaucomas, including, without limitation, high tension glaucoma, low tension glaucoma, and their related diseases.
- the pharmaceutical composition of the present invention is used for prevention or treatment of intraocular hypertension and/or glaucoma.
- the glaucoma prevented or treated by the pharmaceutical composition of the invention is primary open angle glaucoma, normal pressure glaucoma, acute angle closure glaucoma, absolute glaucoma, chronic glaucoma, congenital glaucoma, juvenile glaucoma, narrow angle glaucoma, chronic open angle glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, phacolytic glaucoma, steroid-induced glaucoma, uveitic glaucoma, neovascular glaucoma, toxic glaucoma, traumatic glaucoma or simplex glaucoma.
- the active agent comprised within the pharmaceutical composition of the present invention is R-801, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- R-801 has two asymmetric centers, and may accordingly exist both as enantiomers, i.e., optical isomers (R, S, or racemate, wherein a certain enantiomer may have an optical purity of 90%, 95%, 99% or more) and as diastereoisomers.
- the active agent comprised within the pharmaceutical composition of the invention is thus an enantiomer or diastereomer of R-801, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- Optically active forms of R-801 may be prepared using any method known in the art, e.g., by resolution of the racemic form by recrystallization techniques; by chiral synthesis; by extraction with chiral solvents; or by chromatographic separation using a chiral stationary phase.
- a non-limiting example of a method for obtaining optically active materials is transport across chiral membranes, i.e., a technique whereby a racemate is placed in contact with a thin membrane barrier, the concentration or pressure differential causes preferential transport across the membrane barrier, and separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.
- Chiral chromatography including simulated moving bed chromatography, can also be used.
- a wide variety of chiral stationary phases are commercially available.
- the active agent comprised within the pharmaceutical composition of the present invention is a non-toxic pharmaceutically acceptable salt of R- 801 or an enantiomer, diastereomer, or racemate thereof.
- Suitable pharmaceutically acceptable salts include acid addition salts such as, without being limited to, the mesylate salt, the maleate salt, the fumarate salt, the tartrate salt, the hydrochloride salt, the hydrobromide salt, the esylate salt; the /?-toluenesulfonate salt, the benzoate salt, the acetate salt, the phosphate salt, the sulfate salt, the citrate salt, the carbonate salt, and the succinate salt.
- Additional pharmaceutically acceptable salts include salts of ammonium (NH 4 + ) or an organic cation derived from an amine of the formula (NR 4 + ), wherein each one of the Rs independently is selected from H, Q-C22, preferably Ci-C 6 alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2,2- dimethylpropyl, n-hexyl, and the like, phenyl, or heteroaryl such as pyridyl, imidazolyl, pyrimidinyl, and the like, or two of the Rs together with the nitrogen atom to which they are attached form a 3-7 membered ring optionally containing a further heteroatom selected from N, S and O, such as pyrrolydine, piperidine and morpholine.
- N, S and O such as pyrrolyd
- suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g., lithium, sodium or potassium salts, and alkaline earth metal salts, e.g., calcium or magnesium salts.
- Further pharmaceutically acceptable salts include salts of a cationic lipid or a mixture of cationic lipids.
- Cationic lipids are often mixed with neutral lipids prior to use as delivery agents.
- Neutral lipids include, but are not limited to, lecithins; phosphatidylethanolamine; diacyl phosphatidylethanolamines such as dioleoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, palmitoyloleoyl phosphatidylethanolamine and distearoyl phosphatidylethanolamine; phosphatidylcholine; diacyl phosphatidylcholines such as dioleoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, palmitoyloleoyl phosphatidylcholine and distearoyl phosphatidylcholine; phosphatidylglycerol
- Examples of cationic lipid compounds include, without being limited to, Lipofectin ® (Life Technologies, Burlington, Ontario) (1: 1 (w/w) formulation of the cationic lipid N-[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride and dioleoylphosphatidyl-ethanolamine); LipofectamineTM (Life Technologies, Burlington, Ontario) (3: 1 (w/w) formulation of polycationic lipid 2,3-dioleyloxy-N-[2(spermine- carboxamido)ethyl] - ⁇ , ⁇ -dimethyl- 1 -propanamin-iumtrifluoroacetate and dioleoylphosphatidyl-ethanolamine), Lipofectamine Plus (Life Technologies, Burlington, Ontario) (Lipofectamine and Plus reagent), Lipofectamine 2000 (Life Technologies, Burlington, Ontario) (Cationic lipid), Effectene (
- the active agent comprised within the pharmaceutical composition of the present invention is a prodrug of R-801, or enantiomer, diastereomer, or racemate thereof.
- prodrug refers to a compound that can be metabolized or converted in vivo, in a process termed bioactivation, to provide R-801, or said enantiomer, diastereomer, or racemate thereof.
- Such a prodrug may be, e.g., a compound corresponding to R-801 wherein the nitroxide group is protected to form an ester group that is hydrolyzed, in vivo, to the corresponding hydroxylamine or N-hydroxyl (N-OH) compound, which is then oxidized to provide R-801.
- alkyl typically means a straight or branched saturated hydrocarbon radical having 1-8 carbon atoms and includes, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, ie/t-butyl, n-pentyl, isoamyl, 2,2-dimethylpropyl, n- hexyl, n-heptyl, n-octyl, and the like.
- Preferred are (Ci-C 4 )alkyl groups, e.g., methyl, ethyl and isopropyl.
- alkylene typically means a divalent straight or branched hydrocarbon radical having 1-8 carbon atoms and includes, e.g., methylene, ethylene, propylene, butylene, 2-methylpropylene, pentylene, 2-methylbutylene, hexylene, 2-methylpentylene, 3-methylpentylene, 2,3-dimethylbutylene, heptylene, octylene, and the like.
- cycloalkyl as used herein means a cyclic or bicyclic hydrocarbyl group having 3-10 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, bicyclo[3.2.1]octyl, bicyclo[2.2.1]heptyl, and the like.
- Preferred are (C5-Cio)cycloalkyls, more preferably (C5-C7)cycloalkyls.
- aryl denotes an aromatic carbocyclic group having 6-14 carbon atoms consisting of a single ring or multiple rings either condensed or linked by a covalent bond such as, but not limited to, phenyl, naphthyl, phenanthryl, and biphenyl.
- aryl denotes an aromatic carbocyclic group having 6-14 carbon atoms consisting of a single ring or multiple rings either condensed or linked by a covalent bond such as, but not limited to, phenyl, naphthyl, phenanthryl, and biphenyl.
- the pharmaceutical composition of the present invention can be provided in a variety of formulations and dosages. These compositions may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19 th Ed., 1995, for example by uniformly and intimately bringing the active agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation.
- the ophthalmic composition of the invention intended for direct application to the eye, may be formulated so as to have both pH and tonicity compatible with the eye.
- the composition of the invention has an osmolality in the range of about 50 to about 700 mOsm/kg, preferably 100-600 mOsm/kg, more preferably 150-500 mOsm/kg, 200-400 mOsm/kg, or 200-350 mOsm/kg.
- the ophthalmic composition of the invention may be administered to the eye of the subject treated by any suitable means.
- the composition is in the form of a liquid, e.g., ophthalmic drops, emulsion, suspension, gel, or ointment of the active agent, and it is administered as drops, spray, or gel.
- the active agent is applied to the eye via liposomes.
- the active agent is contained within a continuous or selective-release device, e.g., membranous ocular eye patches such as, but not limited to, those employed in the OcusertTM System (Alza Corp., Palo Alto, Calif.).
- the active agent is formulated as a depot form, for implanting in, or next to, a treated eye.
- the active agent can be contained within, carried by, or attached to contact lenses, which are placed on the eye.
- the active agent is contained within a swab or sponge, or within a liquid spray, which is applied to the ocular surface.
- the ophthalmic composition as defined in any one of the embodiments above is directly injected into the ocular tissues, e.g., by intracameral, subconjunctival, subscleral, or intravitreal injection, or onto the eye surface.
- the ophthalmic composition of the present invention contain a physiologically compatible carrier or vehicle as those skilled in the ophthalmic art can select using conventional criteria.
- a physiologically compatible carrier or vehicle as those skilled in the ophthalmic art can select using conventional criteria.
- Such vehicles may be selected from known ophthalmic vehicles that include, inter alia, saline solution, water, polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, cyclodextrins, in particular betahydroxypropyl cyclodextrin, petroleum derivatives, e.g., mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as carboxypolymethylene gel, vegetable fats such as peanut oil, polysaccharides such as dex trans, an alginate such as sodium alginate optionally comprising guluronic acid and/or mannuronic acid, glycosamino
- compositions for the treatment of glaucoma may be administered daily, twice daily, or 3-4 times daily, and/or upon the occurrence of symptoms associated with the condition; and over a period of time consistent with treatment of the ocular hypertension and glaucoma, e.g., for a period of weeks, months, years, or decades.
- the present invention relates to R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in reducing IOP, e.g., for prevention or treatment of intraocular hypertension and/or glaucoma.
- the present invention relates to use of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for reducing IOP, e.g., for prevention or treatment of intraocular hypertension and/or glaucoma.
- the present invention relates to a method for reducing IOP thereby, e.g., preventing or treating intraocular hypertension and/or glaucoma, in an individual in need thereof comprising administering to the eye of said individual a therapeutically effective amount of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
- therapeutically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result, i.e., to reduce IOP and consequently treat of prevent intraocular hypertension and/or glaucoma.
- a therapeutically effective amount of an active agent as referred to herein may vary according to factors including the disease state, age, and sex, and the ability of the active agent to elicit a desired response in the subject treated.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the therapeutic agent are outweighed by the therapeutically beneficial effects.
- the effective amount used for prevention of said intraocular hypertension and/or glaucoma may be less than the effective amount used for treatment of said indications.
- the therapeutic agent administered according to the method of the present invention is formulated as ophthalmic drops, emulsion, suspension, gel, ointment, a membranous ocular eye patch, or a depot form.
- said therapeutic agent is formulated for direct injection into the ocular tissue, and is administered to the subject by intracameral, subconjunctival, subscleral, or intravitreal injection, or onto the eye surface.
- the anterior segment was clamped in a modified Petri dish, and the eye was perfused with Dulbecco's modified Eagle's medium (DMEM; Mediatech, Inc., Manassas, VA) containing antibiotics (penicillin, 10,000 U; streptomycin, 10 mg; amphotericin B, 25 mg; and gentamicin, 1.7 mg in 100 mL medium).
- DMEM Dulbecco's modified Eagle's medium
- Anterior segments were maintained at 37°C in a 5% C0 2 atmosphere while being perfused at the normal human flow rate (2.5 ⁇ / ⁇ ).
- Pressure mm Hg was continuously monitored in real time with a pressure transducer connected to a second access cannula built into the modified Petri dish and was recorded with an automated computerized system.
- the baseline pressure in a human cadaver eye was 28 mm Hg (Fig. 2). This initial pressure was higher than normal, but stable. Following R-801 (20 ⁇ ) addition, the pressure dropped to 16 mm Hg. Relatively no change was observed in the vehicle-treated control eye. Perfusion was stopped after 18 hours.
- the inhibition constants were obtained by nonlinear least-squares methods using PRISM 3, whereas the kinetic parameters for the uninhibited enzymes from Lineweaver-Burk plots, as previously reported (Hen et ah, 2011; Scozzafava et ah, 1998; Pacchiano et ah, 2011), represent the mean from at least three different determinations. All CAs were recombinant proteins.
- Scozzafava A.; Supuran, C.T., Carbonic Anhydrase Inhibitor: Ureido and thioureido derivatives of aromatic sulfonamides possessing increased affinities for isozymes I.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Chemistry (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising the oxy radical of 2-cyano-1-(1-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl) guanidine, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reducing intraocular pressure and thereby treating ocular hypertension and/or glaucoma, and to a method of use.
Description
PHARMACEUTICAL COMPOSITION AND METHOD FOR REDUCING
INTRAOCULAR PRESSURE
TECHNICAL FIELD
[0001] The present invention relates to pharmaceutical composition and method for reducing intraocular pressure and thereby treating ocular hypertension and/or glaucoma.
BACKGROUND ART
[0002] Primary open angle glaucoma (POAG) is the most common form of glaucoma, the leading cause of irreversible blindness that affects 60 million people worldwide. Existing agents for treatment of POAG, such as prostaglandins, carbonic anhydrase inhibitors, and beta blockers, are not universally effective in reducing intraocular pressure (IOP) and are laden with various side-effects. Accordingly, patient compliance is low and visual deterioration is frequent, resulting in severe impairment and blindness.
[0003] International Publication No. WO 2012/077108 discloses compounds composed of a potassium channel opener, e.g., a pyridinocyanoguanidine moiety or a derivative thereof, linked to a reactive oxygen species degradation catalyst comprising a nitroxide free radical (NO') group, such as 3-amino-2,2,5,5-tetramethylpyrrolidinyloxy (3-amino- PROXYL), 4-amino-2,2,6,6-tetramethylpipperidinyloxy (4-amino-TEMPO), or a derivative thereof, and pharmaceutical compositions thereof. As shown in said publication, such compounds are useful in treatment, prevention and/or managing of diseases, disorders and conditions associated with oxidative stress or endothelial dysfunction. One of the compounds exemplified in said publication is the oxy radical of 2-cyano-l-(l-hydroxy- 2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl) guanidine, herein identified R-801.
SUMMARY OF INVENTION
[0004] As found in accordance with the present invention, R-801 is a highly potent inhibitor of human type 2 carbonic anhydrase (hCA), an enzyme controlling 95% of inflow into the anterior chamber, and thus highly beneficial, upon administration to the eye, in reducing IOP. This compound can therefore be used for treatment of, e.g., ocular hypertension and/or glaucoma.
[0005] In one aspect, the present invention thus provides a pharmaceutical composition comprising the oxy radical of 2-cyano-l-(l-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3- (pyridin-3-yl)guanidine (R-801), or an enantiomer, diastereomer, racemate, or a
pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier or diluent, for reducing, i.e., lowering, IOP, more particularly for prevention or treatment of intraocular h ertension and/or glaucoma.
R-801
[0006] In another aspect, the present invention relates to R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in reducing IOP.
[0007] In yet another aspect, the present invention relates to use of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for reducing IOP.
[0008] In a further aspect, the present invention relates to a method for reducing, i.e., lowering, IOP in a subject in need thereof comprising administering to the eye of said subject a therapeutically effective amount of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof. The subject treated by the method of the invention may be any mammal such as a human, non-human primate, horse, ferret dog, cat, cow, and goat; but it is preferably a human, i.e., an individual.
BRIEF DESCRIPTION OF DRAWINGS
[0009] Fig. 1 shows that after baseline stabilization of pressure, in anterior segments, the pressure dropped from 16 mmHg to 11 mmHg after R-801 (20 μΜ) was added to a human cadaver eye (♦) while the fellow eye (■) received vehicle (DMSO). After 72 hours of treatment, drug and vehicle were removed from the eyes and perfused with DMEM. Following perfusion, the pressure in the eye that received R-801 returned to near baseline levels (actually a little higher), and relatively no change in pressure was observed in the eye treated with vehicle.
[0010] Fig. 2 shows the effects of R-801-induced pressure reduction, in anterior segments, when the baseline pressure in a human cadaver eye (♦) was 28 mmHg. This initial pressure was higher than normal, but it had a stable baseline. The pressure dropped
from 28 mmHg to 16 mmHg following R-801 treatment. Relatively no change was observed in the vehicle-treated control eye (■). Perfusion was stopped after 18 hours.
[0011] Fig. 3 shows the effects of R-801-induced pressure reduction, in the eye of a monkey that underwent laser treatment to induce ocular hypertension (OHT). IOP was measured with a calibrated pneumatonometer. R-801 treatment by intracameral injection reduced the IOP from 26 mmHg to 12 mmHg during the 30 hour period after treatment and returned to pretreatment levels after 96 hours.
DETAILED DESCRIPTION
[0012] In one aspect, the present invention provides a pharmaceutical composition comprising R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, herein generally referred to as "the active/therapeutic agent", and a pharmaceutically acceptable carrier or diluent, for reducing IOP.
[0013] The terms "intraocular hypertension", "ocular hypertension", or "elevated intraocular pressure", as used herein interchangeably, refer to an intraocular pressure in an eye of a subject (e.g., a patient) that is above a normal level and is correlated as a risk factor for the development of visual field loss and glaucoma.
[0014] Glaucoma is a heterogeneous group of optic neuropathies that share certain clinical features, wherein the loss of vision is due to the selective death of retinal ganglion cells in the neural retina that is clinically diagnosed by characteristic changes in the visual field, nerve fiber layer defects, and a progressive cupping of the optic nerve head. One of the main risk factors for the development of glaucoma is the presence of intraocular hypertension (elevated IOP). IOP also appears to be involved in the pathogenesis of normal tension glaucoma where patients have what is often considered to be normal IOP. The elevated IOP associated with glaucoma is due to elevated aqueous humor outflow resistance in the trabecular meshwork, a small- specialized tissue located in the iris-corneal angle of the ocular anterior chamber. Glaucomatous changes to the trabecular meshwork include a loss in trabecular meshwork cells and the deposition and accumulation of extracellular debris including proteinaceous plaque-like material. In addition, there are also changes that occur in the glaucomatous optic nerve head. In glaucomatous eyes, there are morphological and mobility changes in optic nerve head glial cells. In response to elevated IOP and/or transient ischemic insults, there is a change in the composition of the optic
nerve head extracellular matrix and alterations in the glial cell and retinal ganglion cell axon morphologies.
[0015] The term "glaucoma" as used herein thus refers to a disease of the eye characterized by increased pressure inside the eye with resultant optic nerve damage, and includes, without limiting, primary glaucoma, secondary glaucoma, juvenile glaucoma, congenital glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, phacolytic glaucoma, steroid-induced glaucoma, uveitic glaucoma, neovascular glaucoma, toxic glaucoma, traumatic glaucoma, acute angle closure glaucoma, absolute glaucoma, chronic glaucoma, narrow angle glaucoma, chronic open angle glaucoma, combined-mechanism glaucoma, simplex glaucoma and familial glaucomas, including, without limitation, high tension glaucoma, low tension glaucoma, and their related diseases.
[0016] In certain embodiments, the pharmaceutical composition of the present invention is used for prevention or treatment of intraocular hypertension and/or glaucoma.
[0017] In particular such embodiments, the glaucoma prevented or treated by the pharmaceutical composition of the invention is primary open angle glaucoma, normal pressure glaucoma, acute angle closure glaucoma, absolute glaucoma, chronic glaucoma, congenital glaucoma, juvenile glaucoma, narrow angle glaucoma, chronic open angle glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, phacolytic glaucoma, steroid-induced glaucoma, uveitic glaucoma, neovascular glaucoma, toxic glaucoma, traumatic glaucoma or simplex glaucoma.
[0018] In certain embodiments, the active agent comprised within the pharmaceutical composition of the present invention is R-801, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0019] R-801 has two asymmetric centers, and may accordingly exist both as enantiomers, i.e., optical isomers (R, S, or racemate, wherein a certain enantiomer may have an optical purity of 90%, 95%, 99% or more) and as diastereoisomers. In other embodiments, the active agent comprised within the pharmaceutical composition of the invention is thus an enantiomer or diastereomer of R-801, or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
[0020] Optically active forms of R-801 may be prepared using any method known in the art, e.g., by resolution of the racemic form by recrystallization techniques; by chiral synthesis; by extraction with chiral solvents; or by chromatographic separation using a chiral stationary phase. A non-limiting example of a method for obtaining optically active
materials is transport across chiral membranes, i.e., a technique whereby a racemate is placed in contact with a thin membrane barrier, the concentration or pressure differential causes preferential transport across the membrane barrier, and separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through. Chiral chromatography, including simulated moving bed chromatography, can also be used. A wide variety of chiral stationary phases are commercially available.
[0021] In certain embodiments, the active agent comprised within the pharmaceutical composition of the present invention is a non-toxic pharmaceutically acceptable salt of R- 801 or an enantiomer, diastereomer, or racemate thereof. Suitable pharmaceutically acceptable salts include acid addition salts such as, without being limited to, the mesylate salt, the maleate salt, the fumarate salt, the tartrate salt, the hydrochloride salt, the hydrobromide salt, the esylate salt; the /?-toluenesulfonate salt, the benzoate salt, the acetate salt, the phosphate salt, the sulfate salt, the citrate salt, the carbonate salt, and the succinate salt. Additional pharmaceutically acceptable salts include salts of ammonium (NH4 +) or an organic cation derived from an amine of the formula (NR4 +), wherein each one of the Rs independently is selected from H, Q-C22, preferably Ci-C6 alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2,2- dimethylpropyl, n-hexyl, and the like, phenyl, or heteroaryl such as pyridyl, imidazolyl, pyrimidinyl, and the like, or two of the Rs together with the nitrogen atom to which they are attached form a 3-7 membered ring optionally containing a further heteroatom selected from N, S and O, such as pyrrolydine, piperidine and morpholine. Furthermore, where the active agent carries an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g., lithium, sodium or potassium salts, and alkaline earth metal salts, e.g., calcium or magnesium salts.
[0022] Further pharmaceutically acceptable salts include salts of a cationic lipid or a mixture of cationic lipids. Cationic lipids are often mixed with neutral lipids prior to use as delivery agents. Neutral lipids include, but are not limited to, lecithins; phosphatidylethanolamine; diacyl phosphatidylethanolamines such as dioleoyl phosphatidylethanolamine, dipalmitoyl phosphatidylethanolamine, palmitoyloleoyl phosphatidylethanolamine and distearoyl phosphatidylethanolamine; phosphatidylcholine; diacyl phosphatidylcholines such as dioleoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, palmitoyloleoyl phosphatidylcholine and distearoyl
phosphatidylcholine; phosphatidylglycerol; diacyl phosphatidylglycerols such as dioleoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol and distearoyl phosphatidylglycerol; phosphatidylserine; diacyl phosphatidylserines such as dioleoyl- or dipalmitoyl phosphatidylserine; and diphosphatidylglycerols; fatty acid esters; glycerol esters; sphingolipids; cardiolipin; cerebrosides; ceramides; and mixtures thereof. Neutral lipids also include cholesterol and other 3β hydroxy- sterols.
[0023] Examples of cationic lipid compounds include, without being limited to, Lipofectin® (Life Technologies, Burlington, Ontario) (1: 1 (w/w) formulation of the cationic lipid N-[l-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride and dioleoylphosphatidyl-ethanolamine); Lipofectamine™ (Life Technologies, Burlington, Ontario) (3: 1 (w/w) formulation of polycationic lipid 2,3-dioleyloxy-N-[2(spermine- carboxamido)ethyl] -Ν,Ν-dimethyl- 1 -propanamin-iumtrifluoroacetate and dioleoylphosphatidyl-ethanolamine), Lipofectamine Plus (Life Technologies, Burlington, Ontario) (Lipofectamine and Plus reagent), Lipofectamine 2000 (Life Technologies, Burlington, Ontario) (Cationic lipid), Effectene (Qiagen, Mississauga, Ontario) (Non liposomal lipid formulation), Metafectene (Biontex, Munich, Germany) (Polycationic lipid), Eu-fectins (Promega Biosciences, San Luis Obispo, Calif.) (ethanolic cationic lipids numbers 1 through 12: C52H106N6O44CF3CO2H, C88H178N804S2-4CF3C02H, C40H84NO3P CF3CO2H, C5oH10 N703-4CF3C02H, C55H116N8026CF3C02H,
C49H102N6O34CF3CO2H, C44H89N503-2CF3C02H, CiooH2o6Ni204S28CF3C02H, C162H330N22O9 13CF3CO2H, C43H88N402-2CF3C02H, C43H88N403-2CF3C02H,
C4iH78N08P); Cytofectene (Bio-Rad, Hercules, Calif.) (mixture of a cationic lipid and a neutral lipid), GenePORTER® (Gene Therapy Systems, San Diego, Calif.) (formulation of a neutral lipid (Dope) and a cationic lipid) and FuGENE 6 (Roche Molecular Biochemicals, Indianapolis, Ind.) (Multi-component lipid based non-liposomal reagent).
[0024] In certain embodiments, the active agent comprised within the pharmaceutical composition of the present invention is a prodrug of R-801, or enantiomer, diastereomer, or racemate thereof. The term "prodrug" as used herein refers to a compound that can be metabolized or converted in vivo, in a process termed bioactivation, to provide R-801, or said enantiomer, diastereomer, or racemate thereof. Such a prodrug may be, e.g., a compound corresponding to R-801 wherein the nitroxide group is protected to form an ester group that is hydrolyzed, in vivo, to the corresponding hydroxylamine or N-hydroxyl (N-OH) compound, which is then oxidized to provide R-801. More particular such
prodrugs are those wherein the nitroxide group is protected to form an ester group of the formula =N-0-C(0)-Ri, wherein Ri is (d-C8)alkyl, (C3-Ci0)cycloalkyl, or (C6-Ci4)aryl, optionally substituted with one or more groups each independently selected from -OH, - COR2, -COOR2, -(Ci-C8)alkylene-COOR2, -CN, -N02, -(Ci-C8)alkyl, -0-(Ci-C8)alkyl, - N(R2)2, -CON(R2)2, -SO2R2, -SO2NHR2, or -S(=0)R2; and R2 each independently is H, (Q-Cf alkyl, (C3-C10)cycloalkyl, or (C6-C14)aryl.
[0025] The term "alkyl" as used herein typically means a straight or branched saturated hydrocarbon radical having 1-8 carbon atoms and includes, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, ie/t-butyl, n-pentyl, isoamyl, 2,2-dimethylpropyl, n- hexyl, n-heptyl, n-octyl, and the like. Preferred are (Ci-C4)alkyl groups, e.g., methyl, ethyl and isopropyl.
[0026] The term "alkylene" typically means a divalent straight or branched hydrocarbon radical having 1-8 carbon atoms and includes, e.g., methylene, ethylene, propylene, butylene, 2-methylpropylene, pentylene, 2-methylbutylene, hexylene, 2-methylpentylene, 3-methylpentylene, 2,3-dimethylbutylene, heptylene, octylene, and the like. Preferred are (Ci-C4)alkylene, e.g., methylene, ethylene and propylene.
[0027] The term "cycloalkyl" as used herein means a cyclic or bicyclic hydrocarbyl group having 3-10 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, bicyclo[3.2.1]octyl, bicyclo[2.2.1]heptyl, and the like. Preferred are (C5-Cio)cycloalkyls, more preferably (C5-C7)cycloalkyls.
[0028] The term "aryl" denotes an aromatic carbocyclic group having 6-14 carbon atoms consisting of a single ring or multiple rings either condensed or linked by a covalent bond such as, but not limited to, phenyl, naphthyl, phenanthryl, and biphenyl.
[0029] The term "aryl" as used herein denotes an aromatic carbocyclic group having 6-14 carbon atoms consisting of a single ring or multiple rings either condensed or linked by a covalent bond such as, but not limited to, phenyl, naphthyl, phenanthryl, and biphenyl.
[0030] The pharmaceutical composition of the present invention, herein also referred to as "ophthalmic composition", can be provided in a variety of formulations and dosages. These compositions may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995, for example by uniformly and intimately bringing the active agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulation.
[0031] The ophthalmic composition of the invention, intended for direct application to the eye, may be formulated so as to have both pH and tonicity compatible with the eye. This will normally require a buffer to maintain the pH of the composition at or near physiologic pH, i.e., in the range of about 5 to about 9, preferably about 6 to about 8, more preferably 6.8-7.4; and may further require a tonicity agent to bring the osmolality of the composition to a level at or near 210-320 milliosmoles per kilogram (mOsm/kg). In certain embodiments, the composition of the invention has an osmolality in the range of about 50 to about 700 mOsm/kg, preferably 100-600 mOsm/kg, more preferably 150-500 mOsm/kg, 200-400 mOsm/kg, or 200-350 mOsm/kg.
[0032] The ophthalmic composition of the invention, as defined in any one of the embodiments above, may be administered to the eye of the subject treated by any suitable means. In one embodiment, the composition is in the form of a liquid, e.g., ophthalmic drops, emulsion, suspension, gel, or ointment of the active agent, and it is administered as drops, spray, or gel. In another embodiment, the active agent is applied to the eye via liposomes. In a further embodiment, the active agent is contained within a continuous or selective-release device, e.g., membranous ocular eye patches such as, but not limited to, those employed in the OcusertTM System (Alza Corp., Palo Alto, Calif.). In yet another embodiment, the active agent is formulated as a depot form, for implanting in, or next to, a treated eye.
[0033] In one embodiment, the active agent can be contained within, carried by, or attached to contact lenses, which are placed on the eye. In other embodiments, the active agent is contained within a swab or sponge, or within a liquid spray, which is applied to the ocular surface. In a further embodiment, the ophthalmic composition as defined in any one of the embodiments above is directly injected into the ocular tissues, e.g., by intracameral, subconjunctival, subscleral, or intravitreal injection, or onto the eye surface.
[0034] In addition to the active agent, the ophthalmic composition of the present invention contain a physiologically compatible carrier or vehicle as those skilled in the ophthalmic art can select using conventional criteria. Such vehicles may be selected from known ophthalmic vehicles that include, inter alia, saline solution, water, polyethers such as polyethylene glycol, polyvinyls such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, cyclodextrins, in particular betahydroxypropyl cyclodextrin, petroleum derivatives, e.g., mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as
carboxypolymethylene gel, vegetable fats such as peanut oil, polysaccharides such as dex trans, an alginate such as sodium alginate optionally comprising guluronic acid and/or mannuronic acid, glycosaminoglycans such as sodium hyaluronate, and salts such as sodium chloride and potassium chloride.
[0035] The optimal dosage for administration will depend on the state of the patient, and will be determined as deemed appropriate by the practitioner. In particular, compositions for the treatment of glaucoma may be administered daily, twice daily, or 3-4 times daily, and/or upon the occurrence of symptoms associated with the condition; and over a period of time consistent with treatment of the ocular hypertension and glaucoma, e.g., for a period of weeks, months, years, or decades.
[0036] In another aspect, the present invention relates to R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in reducing IOP, e.g., for prevention or treatment of intraocular hypertension and/or glaucoma.
[0037] In yet another aspect, the present invention relates to use of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for reducing IOP, e.g., for prevention or treatment of intraocular hypertension and/or glaucoma.
[0038] In a further aspect, the present invention relates to a method for reducing IOP thereby, e.g., preventing or treating intraocular hypertension and/or glaucoma, in an individual in need thereof comprising administering to the eye of said individual a therapeutically effective amount of R-801, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0039] The term "therapeutically effective amount" as used herein refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result, i.e., to reduce IOP and consequently treat of prevent intraocular hypertension and/or glaucoma. A therapeutically effective amount of an active agent as referred to herein may vary according to factors including the disease state, age, and sex, and the ability of the active agent to elicit a desired response in the subject treated. A therapeutically effective amount is also one in which any toxic or detrimental effects of the therapeutic agent are outweighed by the therapeutically beneficial effects. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of a disease, the
effective amount used for prevention of said intraocular hypertension and/or glaucoma may be less than the effective amount used for treatment of said indications.
[0040] In certain embodiments, the therapeutic agent administered according to the method of the present invention is formulated as ophthalmic drops, emulsion, suspension, gel, ointment, a membranous ocular eye patch, or a depot form.
[0041] In other embodiments, said therapeutic agent is formulated for direct injection into the ocular tissue, and is administered to the subject by intracameral, subconjunctival, subscleral, or intravitreal injection, or onto the eye surface.
[0042] Unless otherwise indicated, all numbers referring to the pH or osmolarity of the composition of the invention used in the present description and/or claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in this description and attached claims are approximations that may vary by up to plus or minus 10% depending upon the desired properties sought to be obtained by the present invention.
[0043] The invention will now be illustrated by the following non-limiting Examples.
EXAMPLES
Experimental
[0044] Pairs of normal human eyes from adult donors were obtained from the Minnesota Lions Eye Bank and were placed in anterior segment perfusion culture within 12.4+5.5 hours of death. No eyes had glaucoma or were from patients receiving topical eye medications. The culture technique was similar to that described previously (Fautsch et ah, 2000; Fautsch et ah, 2006; Johnson, 1997; Johnson and Tschumper, 1987). Eyes were bisected at the equator, and the iris, lens, and vitreous were removed. The anterior segment was clamped in a modified Petri dish, and the eye was perfused with Dulbecco's modified Eagle's medium (DMEM; Mediatech, Inc., Manassas, VA) containing antibiotics (penicillin, 10,000 U; streptomycin, 10 mg; amphotericin B, 25 mg; and gentamicin, 1.7 mg in 100 mL medium). Anterior segments were maintained at 37°C in a 5% C02 atmosphere while being perfused at the normal human flow rate (2.5 μί/ηιίη). Pressure (mm Hg) was continuously monitored in real time with a pressure transducer connected to a second access cannula built into the modified Petri dish and was recorded with an automated computerized system.
[0045] The use of donor human eyes for this study was approved by the Mayo Clinic Institutional Review Board and conformed to the tenets of the Declaration of Helsinki.
Example 1. Effects of R-801 on pressure in human cadaver anterior segments
[0046] To test whether R-801 has an effect on outflow facility, human cadaver anterior segments were treated with R-801. In the first experiment with anterior segments from human cadavers, when the baseline pressure in the anterior segments was 16 mm Hg, the pressure dropped to 11 mmHg after R-801 (20 μΜ) was added to the culture media (Fig. 1). When vehicle (dimethyl sulfoxide; DMSO) was added to the fellow eye, there was no pressure decrease. After 72 hours of treatment, drug and vehicle were removed from the eyes, and eyes subsequently perfused with DMEM. Following perfusion, the pressure in the eye that received R-801 returned to near baseline levels (actually a little higher). No change in pressure was observed in the eye incubated with DMSO.
[0047] The baseline pressure in a human cadaver eye was 28 mm Hg (Fig. 2). This initial pressure was higher than normal, but stable. Following R-801 (20 μΜ) addition, the pressure dropped to 16 mm Hg. Relatively no change was observed in the vehicle-treated control eye. Perfusion was stopped after 18 hours.
Example 2. Effects of Intracameral R-801 on intraocular pressure
[0048] Two female cynomolgus monkeys (6-7 years) were included in the study. The left eyes had laser treatments to the trabecular meshwork to elevate IOP. A baseline measurement was taken of both the lasered eye (OHT) and contralateral normotensive (NT) eye using pneumotonometer. Prior to treatment, the monkeys were fasted and administered 5 mg/kg ketamine for sedation. Full strength proparacaine was applied topically, and IOP measurements were taken OU (O cuius uterque) to determine the baseline IOP values over three hours. Betadine solution was applied to the lid and surrounding skin and fur of the OHT eye (OS). 20 μΐ of R-801 (0.5 mg/mL) was filtered through a Millipore filter and then injected into the anterior chamber using a 30 gauge needle inserted between the 2 and 3 o'clock position. The needle was withdrawn taking care to minimize the loss of fluid from the anterior chamber. Gentak ointment was administered to the injected eye and the monkey was allowed to recover. IOP measurements were made at 2, 4, 6, 8, 24, 26, 28, 30 and 96 hours after injection. Gentak ointment was applied after each IOP measurement. Buprenorphine (0.01 mg/kg) intramuscularly (IM) was provided for pain management.
[0049] The IOP values measured in the monkey eyes are presented in Fig. 3. While IOP in the vehicle-control eye remained >18 mmHg, R-801 reduced IOP to 12 mmHg. The IOP of the treated eye remained below pretreatment values for 96 hours.
Example 3. Determination of the carbonic anhydrase inhibitory potency of R-801
[0050] An Applied Photophysics stopped-flow instrument was used for assaying the carbonic anhydrase (CA)-catalyzed C02 hydration activity (Khalifah, 1971). Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.4) and 20 mM NaBF4 (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed C02 hydration reaction for a period of 10-100 seconds. The C02 concentrations ranged from 1.7 mM to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5-10% of the reaction were used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (10 mM) were prepared in distilled-deionized water, and dilutions up to 0.01 nM were done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the enzyme-inhibitor complex. The inhibition constants were obtained by nonlinear least-squares methods using PRISM 3, whereas the kinetic parameters for the uninhibited enzymes from Lineweaver-Burk plots, as previously reported (Hen et ah, 2011; Scozzafava et ah, 1998; Pacchiano et ah, 2011), represent the mean from at least three different determinations. All CAs were recombinant proteins.
[0051] Surprisingly, as shown in Table 1, R-801 was found to strongly inhibit carbonic anhydrases II and IV, while it had moderately inhibited carbonic anhydrases I and XII. Carbonic anhydrases II and IV have been found to regulate fluid secretion into the anterior chamber of the eye (Kim et ah, 2002). Therefore, these data support a plausible mechanism of action for providing therapeutic effects in treating glaucoma.
Table 1. Inhibition data with R-801, and acetazolamide as standard, stopped-flow, C02 hydrase assay
Mean from 3 different assys, errors in the range of ±10% of the reported data
REFERENCES
Fautsch, M.P.; Bahler, C.K.; Jewison, D.J.; Johnson, D.H., Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment. Invest Ophthalmol Vis Sci. 2000, 41, 4163-4168
Fautsch, M.P.; Bahler, C.K.; Vrabel, A.M.; Howell, K.G.; Loewen, N.; Teo, W.L.; Poeschla, E.M.; Johnson, D.H., Perfusion of his-tagged eukaryotic myocilin increases outflow resistance in human anterior segments in the presence of aqueous humor. Invest Ophthalmol Vis Sci. 2006, 47, 213-221
Hen, N.; Bialer, M.; Yagen, B.; Maresca, A.; Aggarwal, M.; Robbins, A.H.; McKenna, R.; Scozzafava, A.; Supuran, C.T., Anticonvulsant 4- Aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray Crystallography and Inhibition Studies of Human Carbonic Anhydrase Isoforms I, II, VII, and XIV. J. Med. Chem. 2011, 54, 3977-3981
Johnson, D.H.; Tschumper, R.C.; Human trabecular meshwork organ culture: a new method. Invest Ophthalmol Vis Sci. 1987, 28, 945-953
Johnson, D.H., The effect of cytochalasin D on outflow facility and the trabecular meshwork of the human eye in perfusion organ culture. Invest Ophthalmol Vis Sci. 1997, 38, 2790-2799
Khalifah, R.G., The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. . Biol. Chem. 1971, 246, 2561-2573
Kim, C.Y.; Whittington, D.A.; Chang, J.S.; Liao, J.; May, J. A.; Christiansen, D.W., Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV. J Med Chem. 2002, 45, 888-893
Pacchiano, F.; Carta, F.; McDonald, P.C.; Lou, Y.; Vullo, D.; Scozzafava, A.; Dedhar, S.; Supuran, C.T., Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 2011, 54, 1896-1902
Scozzafava, A.; Supuran, C.T., Carbonic Anhydrase Inhibitor: Ureido and thioureido derivatives of aromatic sulfonamides possessing increased affinities for isozymes I. A novel route to 2, 5-disubstituted-l,3,4-thidiazoles via thioureas and their interaction with isozymes I, II and IV. . Enzyme Inhib. 1998, 13, 103-123
Claims
1. A pharmaceutical composition comprising the oxy radical of 2-cyano-l-(l- hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl)guanidine (herein identified as R-801) or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier or diluent, for reducing intraocular pressure.
2. The pharmaceutical composition of claim 1, for prevention or treatment of intraocular hypertension and/or glaucoma.
3. The pharmaceutical composition of claim 2, wherein the glaucoma is primary open angle glaucoma, normal pressure glaucoma, acute angle closure glaucoma, absolute glaucoma, chronic glaucoma, congenital glaucoma, juvenile glaucoma, narrow angle glaucoma, chronic open angle glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, phacolytic glaucoma, steroid-induced glaucoma, uveitic glaucoma, neovascular glaucoma, toxic glaucoma, traumatic glaucoma or simplex glaucoma.
4. The pharmaceutical composition of any one of claims 1 to 3, formulated as ophthalmic drops, emulsion, suspension, gel, ointment, a membranous ocular eye patch, or a depot form.
5. The pharmaceutical composition of any one of claims 1 to 3, formulated for intracameral injection.
6. The oxy radical of 2-cyano-l-(l-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3- (pyridin-3-yl)guanidine, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for use in reducing intraocular pressure.
7. Use of the oxy radical of 2-cyano-l-(l-hydroxy-2,2,5,5-tetramethylpyrrolidin-3- yl)-3-(pyridin-3-yl)guanidine, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for reducing intraocular pressure.
8. A method for reducing intraocular pressure in a subject in need thereof comprising administering to the eye of said subject a therapeutically effective amount of the oxy radical of 2-cyano-l-(l-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl)
guanidine, or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
9. The method of claim 8, for prevention or treatment of intraocular hypertension and/or glaucoma.
10. The method of claim 9, wherein the glaucoma is primary open angle glaucoma, normal pressure glaucoma, acute angle closure glaucoma, absolute glaucoma, chronic glaucoma, congenital glaucoma, juvenile glaucoma, narrow angle glaucoma, chronic open angle glaucoma, pseudoexfoliation glaucoma, pigmentary glaucoma, phacolytic glaucoma, steroid-induced glaucoma, uveitic glaucoma, neovascular glaucoma, toxic glaucoma, traumatic glaucoma or simplex glaucoma.
11. The method of any one of claims 8 to 10, wherein said oxy radical of 2-cyano-l-(l- hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl)guanidine, or enantiomer, diastereomer, racemate, or pharmaceutically acceptable salt, solvate or prodrug thereof, is formulated as ophthalmic drops, emulsion, suspension, gel, ointment, a membranous ocular eye patch, or a depot form.
12. The method of any one of claims 8 to 10, wherein said oxy radical of 2-cyano-l-(l- hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-(pyridin-3-yl)guanidine, or enantiomer, diastereomer, racemate, or pharmaceutically acceptable salt, solvate or prodrug thereof, is formulated as intracameral injection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662343171P | 2016-05-31 | 2016-05-31 | |
| US62/343,171 | 2016-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017208129A1 true WO2017208129A1 (en) | 2017-12-07 |
Family
ID=59285278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2017/053143 WO2017208129A1 (en) | 2016-05-31 | 2017-05-29 | Pharmaceutical composition and method for reducing intraocular pressure |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017208129A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024102346A1 (en) * | 2022-11-08 | 2024-05-16 | Aisa Pharma, Inc. | Methods of treating eye pain and eye disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012077108A1 (en) | 2010-12-09 | 2012-06-14 | Radikal Therapeutics Inc. | Multifunctional nitroxide derivatives and uses thereof |
-
2017
- 2017-05-29 WO PCT/IB2017/053143 patent/WO2017208129A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012077108A1 (en) | 2010-12-09 | 2012-06-14 | Radikal Therapeutics Inc. | Multifunctional nitroxide derivatives and uses thereof |
Non-Patent Citations (11)
| Title |
|---|
| FAUTSCH, M.P.; BAHLER, C.K.; JEWISON, D.J.; JOHNSON, D.H.: "Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment", INVEST OPHTHALMOL VIS SCI., vol. 41, 2000, pages 4163 - 4168 |
| FAUTSCH, M.P.; BAHLER, C.K.; VRABEL, A.M.; HOWELL, K.G.; LOEWEN, N.; TEO, W.L.; POESCHLA, E.M.; JOHNSON, D.H.: "Perfusion of his-tagged eukaryotic myocilin increases outflow resistance in human anterior segments in the presence of aqueous humor", INVEST OPHTHALMOL VIS SCI., vol. 47, 2006, pages 213 - 221 |
| HEN, N.; BIALER, M.; YAGEN, B.; MARESCA, A.; AGGARWAL, M.; ROBBINS, A.H.; MCKENNA, R.; SCOZZAFAVA, A.; SUPURAN, C.T.: "Anticonvulsant 4-Aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray Crystallography and Inhibition Studies of Human Carbonic Anhydrase Isoforms I, II, VII, and XIV", J. MED. CHEM., vol. 54, 2011, pages 3977 - 3981 |
| JOHNSON, D.H.: "The effect of cytochalasin D on outflow facility and the trabecular meshwork of the human eye in perfusion organ culture", INVEST OPHTHALMOL VIS SCI, vol. 38, 1997, pages 2790 - 2799 |
| JOHNSON, D.H.; TSCHUMPER, R.C.: "Human trabecular meshwork organ culture: a new method", INVEST OPHTHALMOL VIS SCI, vol. 28, 1987, pages 945 - 953 |
| KHALIFAH, R.G.: "The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C", J. BIOL. CHEM., vol. 246, 1971, pages 2561 - 2573, XP008018321 |
| KIM, C.Y.; WHITTINGTON, D.A.; CHANG, J.S.; LIAO, J.; MAY, J.A.; CHRISTIANSON, D.W.: "Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV", J MED CHEM, vol. 45, 2002, pages 888 - 893 |
| PACCHIANO, F.; CARTA, F.; MCDONALD, P.C.; LOU, Y.; VULLO, D.; SCOZZAFAVA, A.; DEDHAR, S.; SUPURAN, C.T.: "Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis", J. MED. CHEM., vol. 54, 2011, pages 1896 - 1902, XP002680226, DOI: doi:10.1021/jm101541x |
| SCOZZAFAVA, A.; SUPURAN, C.T.: "Carbonic Anhydrase Inhibitor: Ureido and thioureido derivatives of aromatic sulfonamides possessing increased affinities for isozymes I. A novel route to 2, 5-disubstituted-1,3,4-thidiazoles via thioureas and their interaction with isozymes I, II and IV", J. ENZYME INHIB., vol. 13, 1998, pages 103 - 123 |
| UTTIO ROY CHOWDHURY ET AL: "ATP-Sensitive Potassium (K ATP ) Channel Activation Decreases Intraocular Pressure in the Anterior Chamber of the Eye", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 52, no. 9, 16 August 2011 (2011-08-16), US, pages 6435, XP055384210, ISSN: 1552-5783, DOI: 10.1167/iovs.11-7523 * |
| UTTIO ROY CHOWDHURY ET AL: "ATP-Sensitive Potassium (K ATP ) Channel Openers Diazoxide and Nicorandil Lower Intraocular Pressure In Vivo", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, vol. 54, no. 7, 22 July 2013 (2013-07-22), US, pages 4892, XP055384214, ISSN: 1552-5783, DOI: 10.1167/iovs.13-11872 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024102346A1 (en) * | 2022-11-08 | 2024-05-16 | Aisa Pharma, Inc. | Methods of treating eye pain and eye disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11185538B2 (en) | Compositions for treating glaucoma or reducing intraocular pressure | |
| JP6876047B2 (en) | Compounds for the treatment of diseases associated with mitochondrial reactive oxygen species (ROS) production | |
| US6069150A (en) | Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents | |
| PT2151438E (en) | Pharmaceutical containing ppar-delta agonist | |
| RU2352337C2 (en) | Inhibitors of histondeacetylase for treatment of ophthalmologic neovascular disturbances and diseases | |
| KR20220125326A (en) | A method of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic protoporphyria with a glycine transport inhibitor. | |
| US20160024178A1 (en) | Compounds for treating neurodegenerative proteinopathies | |
| WO2017208129A1 (en) | Pharmaceutical composition and method for reducing intraocular pressure | |
| BR112015010428B1 (en) | uses of a composition | |
| US20220389023A1 (en) | Compounds, compositions, and methods for protein degradation | |
| US20030171379A1 (en) | Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds | |
| US20210179543A1 (en) | Calpain-2 selective inhibitor compounds for treatment of glaucoma | |
| AU2007234903B2 (en) | Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma | |
| US20150174095A1 (en) | Pharmaceutical compositions for the treatment of visual system disorders | |
| Naftchi | Spinal cord injury | |
| US3670087A (en) | Method of lowering intraocular pressure | |
| JPWO2004091662A1 (en) | Corneal sensory recovery agent | |
| CA2187361A1 (en) | Pharmaceutical composition for treating glaucoma containing terazosin | |
| JP2005213159A (en) | Neovascularization inhibitor and vascular retraction agent | |
| CA2434691A1 (en) | Use of propentofylline to control intraocular pressure | |
| JP2003104909A (en) | Glaucoma-treatment agent containing compound having pi3 kinase-inhibiting action as active ingredient | |
| JPH10218766A (en) | Lacrimation-accelerating and keratoconjunctive disorder-treating agent | |
| WO2007013147A1 (en) | Angiogenesis inhibitor and vascular regressive agent | |
| KR20050036195A (en) | A novel use of riluzole for treating retinopathy | |
| JP2004189735A (en) | Remedy for glaucoma containing compound having lim kinase inhibitory action as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17735629 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17735629 Country of ref document: EP Kind code of ref document: A1 |